Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 347 staff and has a trailing 12-month revenue of around USD$82.9 million.
|Latest market close||USD$16.21|
|52-week range||USD$10.92 - USD$29.61|
|50-day moving average||USD$15.1911|
|200-day moving average||USD$17.7197|
|Wall St. target price||USD$31.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.55|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||-0.55%|
|1 month (2020-10-23)||2.86%|
|3 months (2020-08-25)||11.18%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||-4.93%|
|2 years (2018-11-23)||54.23%|
|3 years (2017-11-24)||44.35%|
|5 years (2015-11-25)||-13.32%|
|Revenue TTM||USD$82.9 million|
|Gross profit TTM||USD$-83,854,000|
|Return on assets TTM||-34.45%|
|Return on equity TTM||-178.43%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 15.0 million Karyopharm Therapeutics shares held short by investors – that's known as Karyopharm Therapeutics's "short interest". This figure is 3.9% up from 14.4 million last month.
There are a few different ways that this level of interest in shorting Karyopharm Therapeutics shares can be evaluated.
Karyopharm Therapeutics's "short interest ratio" (SIR) is the quantity of Karyopharm Therapeutics shares currently shorted divided by the average quantity of Karyopharm Therapeutics shares traded daily (recently around 1.3 million). Karyopharm Therapeutics's SIR currently stands at 11.71. In other words for every 100,000 Karyopharm Therapeutics shares traded daily on the market, roughly 11710 shares are currently held short.
However Karyopharm Therapeutics's short interest can also be evaluated against the total number of Karyopharm Therapeutics shares, or, against the total number of tradable Karyopharm Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karyopharm Therapeutics's short interest could be expressed as 0.2% of the outstanding shares (for every 100,000 Karyopharm Therapeutics shares in existence, roughly 200 shares are currently held short) or 0.2144% of the tradable shares (for every 100,000 tradable Karyopharm Therapeutics shares, roughly 214 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Karyopharm Therapeutics.
Find out more about how you can short Karyopharm Therapeutics stock.
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $10.92 up to $29.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 1.0927. This would suggest that Karyopharm Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOÂ), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.